AN ORALLY ADMINISTERED DRUG FORM COMPRISING A GLYCOSIDIC ANTIBIOTIC AND AN ADJUVANT

Abstract: A drug form is provided for increasing the oral absorption of glycosidic and related antibiotics such as marcrolide, aminoglycoside, lincomycin and anthracycline antibiotics and related chemical species by the oral administration of said glycosidic and related antibiotics in a suitable phar­ maceutically accepted excipient to which has been added a hydroxyaryl or hydroxyaralkyl acid or salt amide or ester thereof. The hydroxyaryl, a hydroxyaralkyl or salt amide or ester thereof is present in the drug form in quantities sufficient to be effective in enhancing the rate of oral absorption of glycosidic and related antibiotic.

Description: TITLE OF THE INVENTION AN ORALLY ADMINISTERED DRUG FORM COMPRISING A GLYCOSIDIC OR RELATED ANTIBIOTIC AND AN ADJUVANT BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to the oral delivery of glycosidic and related antibiotics which by this route are poorly absorbed and more especially to the enhancement of this aelivery by formulations which contain a hydroxyaromatic acid. As employed in this application, the term "glycosidic and related antibiotics" refers to those antibiotics which contain a carbohydrate moiety which is attached through a glycosidic bond and includes such antibiotics as the macrolides, aminoglycosides, lincomycins and anthracyclines. DESCRIPTION OF THE PRIOR ART It is well known to the art that a number of antibiotics are only slowly absorbed from the gastrointestinal tract. Consequently, said antibiotic must be administered by the intravenous or intramuscular route or in excessively large oral doses in order to attain clinical efficacy. The ss-lactam antibiotics is one class of antibiotics which is poorly absorbed by the oral route. Similarly, the glycosidic and related antibiotics, which are chemically characterized by a chemical structure which includes a carbohydrate moiety bonded to the remainder of the molecule by a glycosidic linkage, are poorly absorbed by the oral route. The glycosidic and related antibiotics, such as the macrolide, aminoglycoside, lincomycin, anthracycline and other chemically related antibiotics, are poorly absorbed from the gastrointestinal tract because of two properties, hydrophilicity and/or acid instability. The hydrophilic, polar nature of these antibiotics precludes their rapid absorption so that even the small percentage which is absorbed is subject to a long residency time in the acidic gastric environment. It is therefore clear that any factor which enhances the rate of absorption will demonstrate improved clinical efficacy. Many attempts have been made to improve the oral absorption of glycosidic and related antibiotics. Acid instability is partially overcome by coating the antibiotic with an acid stable-base labile enteric coating. This procedure has achieved some success with the acid labile, macrolide antibiotic, erythromycin; however, this procedure still does not allow complete absorption. Other approaches center on the reduction of the hydrophilicity of the glycosidic and related antibiotics by preparing chemical derivatives which are more lipophilic, see Murphy, Antibiotic Annual 1953-1954, page 500; Stephens, Antibiotic Annual 1958-1959, page 346; and Jones, Journal of Medicinal Chemistry, Volume 15, page 631, 1972. These lipophilic esters of erythromycin show enhanced blood levels when administered to warm-blooded animals. The many attempts to enhance the oral absorption of glycosidic and related antibiotics have met with limited success with the macrolide antibiotics such as erythromycin and oleandomycin and with the lincomycin antibiotics. In these cases specialty coatings and lipophilic chemical derivatives have demonstrated improved absorption from the gastrointestinal tract, but in most cases absorption is incomplete. When similar techniques were applied to the aminoglycoside and anthracycline antibiotics, little or no oral absorption was reported. There is no oral dosage form for either of these two important classes of antibiotics. Thus, there exists a clear and present need for a novel method to enhance the oral absorption of glycosidic and related antibiotics. Said method would permit the oral use of the aminoglycoside and anthracycline antibiotics and provide an improved oral form for the macrolide and lincomycin antibiotics. SUMMARY OF THE INVENTION Accordingly, a major object of this invention is to provide a novel class of agents which enhance the oral absorption of glycosidic and related antibiotics. Another object is to provide a process utilizing said novel class of agents to enhance the oral absorption of glycosidic and related antibiotics. Another object is to provide a stable drug form utilizing said novel class of agents which when administered orally will provide increased blood levels of the therapeutic agent. Other objects, features and advantages of the invention will be apparent to those skilled in the art from the detailed description of the invention which follows. All of the foregoing objects are readily attained by providing a method and drug form wherein the oral absorption of glycosidic and related antibiotics is enhanced, the method comprising the steps of preparing a drug form suitable for oral delivery, and a drug form comprising an effective unit dosage amount of the glycosidic or related antibiotic, a hydroxyaryl or hydroxyaralkyl acid or salt, amide or ester thereof, the latter adjuvants being present in said drug form in an amount sufficient to be effective in enhancing the rate of the oral absorption of the antibiotic and a suitable pharmaceutically accepted excipient. DETAILED DESCRIPTION OF THE INVENTION The present invention, generally comprises the steps of preparing a drug form capable of being orally administered, wherein the drug form comprises an effective unit dosage amount of a glycosidic or related antibiotic and a hydroxyaryl or hydroxyaralkyl acid or salt, amide or ester thereof, the hydroxyaryl or hydroxyaralkyl acid or salt ester or amide thereof being present in the drug form in a sufficient quantity to be effective in enhancing the oral absorption rate and administering the drug form to warm-blooded animals. The amount of glycosidic and related antibiotic varies over a wide range, but generally any therapeutically effective unit dosage amount of the selected glycosidic or related antibiotic is used. The hydroxyaryl or hydroxyaralkyl acids or their salts esters or amides thereof that are used as the adjuvants in our method and in our drug forms have the following structural formulae including the various isomers possible within the formulae set forth: EMI5.1 wherein R1 is a radical selected from -C02H, -(CH2)n-COOH, -CH = CH-CO2H, EMI5.2 -SO3H, H2S03H, X (CH2) nC02H, S02NHR4, PO(OH)N(OH)2, PO(OH)OR4, or a pharmaceutically acceptable salt thereof wherein R2 is a radical selected from OH, H, a lower alkoxy radical having 1-10 carbon atoms, a lower alkyl radical having 1-10 carbon atoms, a lower alkenyl radical having 2-5 carbon atoms, a lower alkanoyl radical having 1-5 carbon atoms, a lower alkanoyloxy radical having 1-5 carbon atoms, a carboxy radical, a carbo-lower alkoxy radical having 1-5 carbon atoms, a halo radical, a mono-, di-, or tri-halo lower alkyl radical having 1-5 carbon atoms, an amino radical, a mono- or- di-lower alkyl amino radical having 1-5 carbon atoms, a carbamyl radical, a lower mono- or di-alkyl carbamyl radical wherein the alkyl group has 1-5 carbon atoms, a thio radical, a lower alkyl thio radical wherein the aklyl group has 1-5 carbon atoms, a cyano radical, a lower alkyl sulfone radical wherein the alkyl group has 1-5 carbon atoms, a lower alkyl sulfoxide radical wherein the alkyl group has 1-5 carbon atoms, a nitro radical, N(CN2)2, C(CN)3, an alkynyl radical having 2-6 carbon atoms, a cycloalkyl radical having 3-10 carbon atoms, a cycloalkenyl radical having 3-10 carbon atoms, an aryl radical including phenyl, a hetroaryl radical including thiophenyl and imadazoalyl, or a heterocycloalkyl radical including morphilinyl and piperdinyl, wherein R3 is a straight or branched alkyl radical having 1-6 carbon atoms or a hydroxy radical, wherein R4 is H or a lower alkyl radical having 1-5 carbon atoms, wherein X is 0 or S, wherein n is an integer of 0-5, wherein y is 1 or 2, and when y is 2, both the.R2 radicals,-taken together, can form a ring containing 0, N or S. More preferred adjuvants are those having the formula: EMI6.1 wherein R1 is a radical selected from -CO2H, - (CH2) -COOH, -CH=CH-CO2H, EMI7.1 -SO3H, -CH2SO3H, O(CH2) CO2H or a pharmaceutically acceptable salt thereof wherein R2 is selected from OH, H, a lower alkoxy radical having 1-10 carbon atoms, a lower alkyl radical having 110 carbon atoms, a halo radical, a mono-,di-,or tri- halo lower alkyl radical wherein the alkyl group has 1-5 carbon atoms, a lower alkyl thio radical wherein the alkyl radical has 1-5 carbon atoms, a cyloalkyl radical having 3-10 carbon atoms, or a cycloalkenyl radical having 3-10 carbon atoms and wherein y is an integer of 1 or 2. Highly preferred adjuvants are those having the formula: EMI7.2 wherein R1 is C02H,-(CH2)-COOH, EMI7.3 SO3H, or a pharmaceutically acceptable salt thereof wherein R2 is OH, H, a lower alkoxy radical, including methoxy, ethoxy, butoxy, or octyloxy, a lower alkyl radical including methyl, isopropyl, ethyl, t-butyl, n-butyl, or t-octyl, a halo radical, or a tri-halo lower alkyl radical including trifluoromethyl, and wherein y is an integer of 1 or 2. Specific adjuvants useful in our method and drug forms for enhancing oral absorption of polar bioactive agents include salicyclic acid, resorcylic acid, and gentisic acid. Other hydroxyaryl or hydroxyaralkyl acids, such as l-hydroxy-2-naphthoic acid, naphthoresorcylic acid, ferulic acid, caff-eic acid, and homovanillic acid, have similar useful adjuvant activity in our process. Such adjuvants are not considered novel per se and may be prepared by techniques known to those skilled in the art. The amount of hydroxyaryl or hydroxyaralkyl acids or salt ester or amide thereof used in our method and drug forms may vary over a wide range; in general, the identity and the amount of the hydroxyaryl or hydroxyaralkyl acid or salt ester or amide thereof is used in connection with drug in order to be effective in enhancing the absorption rate of the drug from the gastrointestinal compartment into the bloodstream. The effectiveness of the hydroxyaryl or hdroxyarakyl acid adjuvants becomes significant at local concentration exceeding 0.01% at the absorption site. Their use at a dosage whereby their concentration at the absorption site exceeds 5% is not recommended because of the local irritating effect on the tissue. The glycosidic and related antibiotics whose enhanced oral delivery is a subject of the present invention encompass a variety of therapeutic agents such as the xanthines, triamterene and theophylline, the anti tumour agents, 5-fluoroouridinedeoxyriboside, 6-mercaptopurinedeoxyriboside, vidarabine, the narcotic analgesics, hydromorphone, cyclazine, pentazocine, bupomorphine, the compounds containing organic anions, heparin, prostaglandins and prostaglandin-like compounds, cromolyn sodium, carbenoxolone, the polyhydroxylic compounds, dopamine, dobutamine, l-dopa, a-methyldopa, the polypeptides, angiotensin antagonists, bradykinin, insulin, ACTH, enkaphaline, endodrphin, somatostatin, secretin and the miscellaneous compounds such as tetracyclines, bromocriptine, lidocaine, cimetidine or any related compounds. The quantity of these polar bioactive agents necessary for preparing the drug form could vary over a wide range, but would normally be regulated by that quantity necessary to comprise the therapeutically effective dosage form. The following combinations of glycosidic and related antibiotics and hydroxyaryl or hydroxy aralkyl acids were given to beagle dogs by gavage. The urine was collected by catheterization and blood by venous puncture. Example Glycosidic Antibiotic Hydroxyaryl or Hydroxyaralkyl Acid 1 erythromycin sodium salicylate 2 oleandomycin salicylic acid 3 spiramicin gentistic acid 4 berythromycin ferulic acid 5 kitasamycin naphthoresorcylic acid 6 erythromycin caffeic acid 7 lincomycin sodium salicylate 8 clindamycin salicylic acid 9 lincomycin gentisic acid 10 clinadamycin sodium gentisate 11 gentamicin sodium ferulate 12 kanamycin resorcylic acid 13 neomycin sodium gentisate 14 paromycin salicylic acid 15 streptomycin caffeic acid 16 tobramycin l-hydroxy-2-naphthoic acid 17 kanamycin homovanillic acid 18 gentamicin sodium salicylate 19 neomycin ferulic acid 20 viomycin caffeic acid 21 butirosin sodium homovanillate 22 sisomycin salicylic acid 23 netilmicin sodium salicylate 24 daunamycin gentisic acid 25 doxorubicin sodium ferulate 26 mithramycin salicylic acid The drug forms of this invention are suitably administered in oral dosage form, such as by tablet or capsule, by combining the glycosidic or related antibiotic in a therapeutic amount and the hydroxyaryl or hydroxyaralkyl acid or salt ester or amide thereof in a sufficient quantity to be effective to enhance oral delivery with an oral pharmaceutically acceptable inert carrier, such as lactose, starch (pharmaceutical grade), dicalcium phosphate, calcium sulfate, Kaolin, mannitol nd powdered sugar. In order to reduce the irritation in the stomach, the preferred dose form of the hydroxyaryl or hydroxyaralkyl acid should be a pharmaceutically acceptable salt and the drug form should be designed to release the glycosidic or related antibiotic and the hydroxyaryl or hydroxyaralkyl acid salt beyond the pylorus. In addition, when required, suitable binders, lubricants, disintegrating agents, and coloring agents can also be added. Typical binders include, without limitation, starch, gelatin, sugars such as sucrose, molasses, and lactose, natural and synthetic gums, such as acacia, sodium alginate, extract of Irish moss, carboxymethylcellulose, methylcellulose, and polyvinylpyrrolidone, polyethylene glycol, ethylcellulose and waxes. Typical lubricants for use in these dosage forms can include, without limitation, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine and polyethylene glycol. Suitable disintegrators can include, without limitation, starch, methylcellulose, agar, bentonite, cellulose and wood products, alginic acid, guar gum, citris pulp, carboxymethylcellulose, and sodium lauryl sulfate. Optionally, if desired, a conventionally, pharmaceutically acceptable dye can be incorporated into the oral dosage unit form, e.g., any of the standard FD & BR< C dyes. EXAMPLE I Preparation of Sodium 2-hydroxy-5-methoxy benzenesulfonate p-Methoxyphenol (12.4 g) was dissolved in chloroform (100 ml) and cooled in ice. Chlorosulfonic acid (11.6 g) was added dropwise to the stirred reaction mixture. The cooling bath was removed after the addition and stirring continued for 24 hours at room temperature. The chloroform was then evaporated off and the residue was vacuum dried to a hygroscopic light brown solid weighing 20.5 g which was 2-hydroxy-5-methoxy-benzenesulfonic acid. NMR (CDC13) 3.73 (3H, s, OCH3)r 6.8-7.2 (3H, m, aromatic H), and 9.86 (2H, broad s, OH and SO3H). IR (film) 3500-2900, 1512, 1470, 1229, 1198, 996, 938 cm 1 The above sulfonic acid (10 g) was dissolved in water (10 ml) and poured into 75 ml of saturated sodium chloride solution. A white solid separated immediately. It was filtered and dried. Crystallization from water gave the pure sodium salt of 2-hydroxy-5-methoxybenzenesulfonic acid (6.6 g). NMR (D2O) 3.83 (3H, s, OCH3), 7.05 and 7.33 (3H, multiplets, aromatic). IR (KBr) 3260, 1518, 1440, 1300, 1280, 1240, 1210, 1905, 1045cm 1. Typical preparation of enteric-coated tablets containing adjuvant. EXAMPLE II Typical preparation of enteric coated tablets containing adjuvant 300 mg Gentamycin Capsules Equal weights of gentamycin sulfate and sodium 5-methoxysalicylate were mixed and 600 mg of the mixture was used to fill No. 00 hard gelatin capsules. A small drop of water around the shell overlap was used to seal the capsules. Coating: The capsules were coated with 25 mg of pre-coat and 65 mg of enteric coating according to the coating procedure described below. Enteric Coating Procedure Tablets or capsules were placed in a coating pan containing baffles to provide adequate tumbling. A small amount of the coating solution was applied using an air sprayer and the solvents evaporated with a warm air supply directed into the coating pan. This procedure was repeated until the desired amount of coating material was applied. The amount of coating material was determined from the weight gain of a representative group of tablets. Coating Solutions: Pre-coat: A film of hydroxypropylmethylcellulose was applied to the tablets followed by an enteric coating. Enteric coat: A film of hydroxypropylmethylcellulosephthalate was applied. Solutions: A 5% by weight solution of hydroxypropylmethylcellulose and a 10% by weight solution of hydroxypropylmethylcellulosephthalate in ethanol:methylene chloride (1:1 by weight) were used as the coating solutions. EXAMPLE III The following adjuvants or their corresponding acids can be used in addition to those previously mentioned in the example above and with the glycosidic and related antibiotics previously mentioned. Sodium 5-methoxysalicylate Sodium salicylate Sodium homovanilate Sodium 2,5-dihydroxybenzoate Sodium 2,4-dihydroxybenzoate Sodium 3,4-dihydroxymandelate Sodium 3-methoxy-4-hydroxymandelate Sodium 3-methoxy-4-hydroxycinnamate Sodium-5-methoxy-2-hydroxyphenylsulfonate Sodium 3-methylsalicylate Sodium 5-methylsalicylate Sodium 5-tert-octylsalicylate Sodium 3-tert-butyl-5-methylsalicylate Sodium guaicolsulfonate Sodium 5-bromosalicylate Sodium 3,5-dibromosalicylate Sodium 5-iodosalicylate Sodium 3,5-diiodosalicylate Sodium 2-hydroxyphenylacetate Sodium 3-hydroxy-2-naphthoate Sodium mandelate Sodium phenyllatate Sodium 2-hydroxyphenylmethanesulfonate Sodium 5-trifluoromethyl-2-hydroxybenzoate Sodium 4-hydroxy-3-hydroxyphenylmethanesulfonate Sodium 3-methoxysalicylate Sodium 5-octyloxysalicylate Sodium 5-butoxysalicylate Sodium p-hydroxyphenoxyacetate Sodium 3,4-dihydroxyphenylacetate Sodium 5-chlorosalicylate Sodium 3,4-dihydroxycinnamate Sodium 3,5-dihydroxybenzoate Sodium 2-hydroxy-3-methoxybenzoate Sodium l-hydroxy-2-naphthoate Sodium salicylurate Any skilled artisan concerned with the subject matter of this invention can prepare these oral dosage forms by simply referring to the oral dosage form preparatory procedure outlined in REMINGTON'S PHARMACEUTICAL SCIENCES, Fifteenth Edition (1975), pages 1576 through 1617 inclusive. From the foregoing description, one of ordinary skill in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. As such, such changes and modifications ae properly, equitably, and intended to be, within the full range of the equivalence of the following claims.

Claims: CLAIMS: 1. An orally administered drug form comprising a therapeutically effective amount of glycosidic or related antibiotic and an adjuvant comprising a hydroxy aryl or hydroxy arlkyl and or salt, amide or ester thereof, said adjuvant being present in said drug form in sufficient amount to be effective in enhancing the oral absorption rate of said glycosidic or related antibiotic. 2. The drug form of Claim ,1 wherein said glyco sidic or related antibiotic is macrolide, aminoglycoside, lincomycin, clindamycin or anthracycline. 3. The drug form of Claim '2 wherein said macrolide is erythromycin, oleandomycin, spiramicin or kitasamycin. :4. The drug form of Claim :2 wherein said amino glycoside is gentamicin, kanamycin, neomycin, paromycin, streptomycin, tobramycin, viomycin, butirosin, netilmicin, or sisomycin. 5. The drug form of Claim 2 wherein said anthracycline is daunamycin, doxorubicin or mithramycin. 6. The drug form of anyone of Claims 1 to 5 wherein said adjuvant comprises EMI17.1 wherein R1 is a radical selected from -CO2H, (CH2)n COOH, -CH = CH-CO2H, EMI17.2 -SO3H, -CH2S03H, X(CH2) nCO 2H, S02NHR4, PO(OH)N(OH)2, PO(OH)OR4, or a pharmaceutically acceptable salt thereof wherein R2 is a radical selected from OH, H, a lower alkoxy radical having 1-10 carbon'atoms, a lower alkyl radical having 1-10 carbon atoms, a lower alkenyl radical having 2-5 carbon atoms, a lower alkanoyl radical having 1-5 carbon atoms, a lower alkanoyloxy radical having 1-5 carbon atoms, a carboxy radical, a carbo-lower alkoxy radical having 1-5 carbon atoms, a halo radical, a mono-, di-, or tri-halo lower alkyl radical having 1-5 carbon atoms, an amino radical, a mono- or di-lower alkyl amino radical having 1-5 carbon atoms, a carbamyl radical, a lower mono- or di-alkyl carbamyl radical wherein the alkyl group has 1-5 carbon atoms, a thio radical, a lower alkyl thio radical wherein the aklyl group has 1-5 carbon atoms, a cyano radical, a lower alkyl sulfone radical wherein the alkyl group has 1-5 carbon atoms, a lower alkyl sulfoxide radical wherein the alkyl group has 1-5 carbon atoms, a nitro radical, N(CN2)2, C(CN)3, an alkynyl radical having 2-6 carbon atoms, a cycloalkyl radical having 3-10 carbon atoms, a cycloalkenyl radical having 3-10 carbon atoms, an aryl radical, a hetroaryl radical including thiophenyl and imadazoalyl, or a heterocycloalkyl radical, wherein R3 is a straight or branched alkyl radical having 1-6 carbon atoms or a hydroxy radical, wherein R4 is H or a lower alkyl radical having 1-5 carbon atoms, wherein X is 0 or S, wherein n is an integer of 0-5. wherein y is 1 or 2, and when y is 2, both the R2 radicals, taken together, can form a ring containing 0, N or S. .7. The drug form of anyone of Claims 1 to 5 wherein said adjuvant comprises EMI18.1 wherein R1 is a radical selected from -CO2H,-(CH2 ) -COOH, CH=CH-CO2H, EMI18.2 -CH2SO3H, O(CH2) CO2H or a pharmaceutically acceptable salt thereof, wherein R2 is selected from OH, H, a lower alkoxy radical having 1-10 carbon atoms, a lower alkyl radical having 1-10 carbon atoms, a halo radical, a mono-, di-, or tri- halo lower alkyl radical wherein the alkyl group has 1-5 carbon atoms, a lower alkyl thio radical wherein the alkyl radical has 1-5 carbon atoms, a cyloalkyl radical having 3-10 carbon atoms, or a cycloalkenyl radical having 3-10 carbon atoms and wherein y is an integer of 1 or 2. 8. The drug form of anyone of Claims 1 to 5 wherein said adjuvant comprises EMI19.1 wherein R1 is CO2H, (CH2) COOH, EMI19.2 SO3H, or a pharmaceutically acceptable salt thereof. wherein R2 is OH, H, lower alkoxy radical, a lower alkyl radical, a halo radical, or a tri-halo lower alkyl radical, and wherein y is an integer of 1 or 2. 9. The drug form of anyone of Claims 1 to 5 wherein said adjuvant is 5-methoxysalicylic acid, salicylic acid, homòvanillic acid; 2,5-dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 3,4-dihydroxymandelic acid; 3-methoxy-4-hydroxy-cinnamic acid; 5-methoxy-2hydroxyphenylsulfonic acid; 3-methylsalicylic acid; 5-methylsalicylic acid; 5-tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic acid; 3,5-diisopropylsalicylic acid; 3-tert-butyl-5methylsalicylic acid; guaicolsulfonic acid; 5-bromosalicylic acid; 3,5-dibroamosalicylic acid; 5-iodosalicylic acid; 3,5-diiodosalicylic acid; 3,5-diiodosalicylic acid; 2-hydroxyphenylacetic acid; 3-hydroxy-2-naphthoic acid; mandelic acid;'phenyllactic acid; 2-hydroxyphenylmethanesulfonic acid; 5-trifluoromethyl-2-hydroxybenzoic acid; 4-hydroxy-3-hydroxyphenylmethanesulfonic acid; 3-methoxysalicylic acid; 5-octyloxysalicylic acid; 5-butoxysalicylic acid; p-hydroxyphenoxyacetic acid; 3,4-dihydroxyphenylacetic acid; 5-chlorosalicylic acid; 3,4 dihydroxycinnamic acid; 3,5-dihydroxybenzoic acid; 2-hydroxy-3-methoxybenzoic acid; l-hydroxy-2-naphthoic acid; salicyluric acid; or the sodium salts thereof. 10. The drug form of anyone of Claims 1 'to 5 wherein the adjuvant is salicylic acid or sodium salicylate. CLAItIS FOR AUSTRIA 1. A method of enhancing the rate of absorption of an orally administered glycosidic or related antibiotic into the bloodstream, said method comprising the steps of preparing a drug form capable of being orally absorbed, said drug form comprising a therapeutically effective dosage amount of the glycosidic or related antibiotic and an adjuvant of a hydroxy aryl or hydroxyaralkyl acid or salt ester or amide thereof, said adjuvant being present in said drug form in a sufficient amount to be effective in enhancing said oral absorption rate. 2. The method of Claim 1 wherein said glycosidic or related antibiotic is macrolide, an aminoglycoside, lincomycin, clindamycin or anthracycline. 3. The method of Claim 2 wherein said macrolide is erythromycin, oleandomycin, spiramicin or kitasamycin. 4. The method of Claim 2 wherein said aminoglycoside is gentam, kanamycin, neomycin, paromycin, streptomycin, tobramycin, viomycin, butirosin, netilmicin or sisomycin. 5. The method of Claim 2 wherein said anthracycline is daunamycin, doxorubicin, mithramycin. 6. The method of anyone of Claims 1 to 5 wherein said adjuvant comprises EMI22.1 wherein R1 is a radical selected from -CO2H, (CH2)nCOOH -CH = CH-CO2H, EMI22.2 -S03H, -CH2SO3H, X(CH2)nCO2H, SO2NHR4, PO(OH)N(OH)2, PO(OH)OR4, or a pharmaceutically acceptable salt thereof wherein R2 is a radical selected from OH, H, a lower alkoxy radical having 1-10 carbon atoms, a lower alkyl radical having 1-10 carbon atoms, a lower alkenyl radical having 2-5 carbon atoms, a lower alkanoyl radical having 1-5 carbon atoms, a lower alkanoyloxy radical having 1-5 carbon atoms, a carboxy radical, a carbo-lower alkoxy radical having 1-5 carbon atoms, a halo radical, a mono-, di-, or tri-halo lower alkyl radical having 1-5 carbon atoms, an amino radical, a mono-or di-lower alkyl amino radical having 1-5 carbon atoms, a carbamyl radical, a lower mono- or di-alkyl carbamyl radical wherein the alkyl group has 1-5 carbon atoms, a thio radical, a lower alkyl thio radical wherein the aklyl group has 1-5 carbon atoms, a cyano radical, a lower alkyl sulfone radical wherein the alkyl group has 1-5 carbon atoms, a lower alkyl sulfoxide radical wherein the alkyl group has 1-5 carbon atoms, a nitro radical, N(CN2)2, C(CN)3, an alkynyl radical having 2-6 carbon atoms, a cycloalkyl radical having 3-10 carbon atoms, a cycloalkenyl radical having 3-10 carbon atoms, an aryl radical, a hetroaryl radical including thiophenyl and imadazoalyl, or a heterocycloalkyl radical, wherein R3 is a straight or branched alkyl radical having 1-6 carbon atoms or a hydroxy radical, wherein R4 is H or a lower alkyl radical having 1-5 carbon atoms, wherein X is O or S, wherein n is an integer of 0-5, wherein y is 1 or 2, and when y is 2, both the R2 radicals, taken together, can form a ring containing 0, N or S. 7. The method of anyone of Claims 1 to 5 wherein said adjuvant comprises EMI23.1 wherein R1 is a radical selected from -CO2H, -(CH2) -COOH, -CH=CH-CO2H, EMI23.2 -503H, -CH2SO3H, O(CH2) CO2H or a pharmaceutically acceptable salt thereof. wherein R2 is selected from OH, H, a lower alkoxy radical having 1-10 carbon atoms, a lower alkyl radical having 1-10 carbon atoms, a halo radical, a mono-, di-, or tri-halo lower alkyl radical wherein the alkyl group has 1-5 carbon atoms, a lower alkyl thio radical wherein the alkyl radical has 1-5 carbon atoms, a cyloalkyl radical having 3-10 carbon atoms, or a cycloalkenyl radical having 3-10 carbon atoms and wherein y is an integer of 1 or 2. 8. The method of anyone of Claims 1 to 5 wherein said adjuvant comprises EMI24.1 wherein R1 is CO2H, (CH2) COOH, EMI24.2 SO3H, or a pharmaceutically acceptable salt thereof. wherein R2 is OH, H, a lower alkoxy radical, a lower alkyl radical a halo radical, or a tri-halo lower alkyl radical, and wherein y is an integer of 1 or 2. 9. The method of anyone of Claims 1 to 5 wherein said adjuvant is 5-methoxysalicylic acid, salicylic acid, homovanillic acid; 2,5-dihydroxybenzoic acid; 2,4-dihydroxybenzoic acid; 3,4-dihydroxymandelic acid; 3-methoxy-4-hycroxycinnamic acid; 5-methoxy-2-hydroxyphenylsulfonic acid; 3-methylsalicylic acid; 5-methylsalicylic acid; 5-tert-octylsalicylic acid; 3-tert-butyl-6-methylsalicylic acid; 3,5-diisopropylsalicylic acid; 3-tert-butyl-5-methylsalicylic acid; guaicolsulfonic acid; 5-bromosalicylic acid; 3,5-dibroamosalicylic acid; 5iodosalicylic acid; 3,5-diiodosalicylic acid; 3,5diiodosalicylic acid; 2-hydroxyphenylacetic acid; 3hydroxy-2-naphthoic acid; mandelic acid; phenyllactic acid; 2-hydroxyphenylmethanesulfonic acid; 5-trifluoromethyl-2-hydroxybenzoic acid; 4-hydroxy-3-hydroxyphenylmethanesulfonic acid; 3-methoxysalicylic acid; 5-octyloxysalicylic acid; 5-butoxysalicylic acid; p-hydroxyphenoxyacetic acid; 3,4-dihydroxyphenylacetic acid; 5-chlorosalicylic acid; 3,4-dihydroxycinnamic acid; 3,5-dihydroxybenzoic acid; 2-hydroxy-3-methoxybenzoic acid; l-hydroxy-2-naphthoic acid; salicyluric acid; or the sodium salts thereof. 10. The meted of anyone of Claims 1 to 5 wherein the adjuvant is salicylic acid or sodium salicylate.

Inventors: HIGUCHI, TAKERU, NISHIHATA, TOSHIAKI
Applicants: INTERX RESEARCH CORPORATION
Application year: 1981
Main classification: A61K31
IPC codes: A61K47, A61K9, A61P31, A61K45